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BackgroundzzMyasthenia gravis (MG) is occasionally aggravated by chronic infection, of which 
there are many kinds.
Case ReportzzWe report herein the case of a 56-year-old woman with MG aggravated by the 
activation of isolated mediastinal tuberculous lymphadenitis (MTL) during corticosteroid admin-
istration. The possibility of MTL had been disregarded in the differential diagnosis of aggravation 
of MG weakness, because MTL without pulmonary manifestations is uncommon even in areas 
where tuberculosis is endemic.
ConclusionszzThis case suggests that chronic infections such as tuberculosis should be consid-
ered in myasthenic patients with progressive exacerbation if definite evidence for aggravating 
factors of MG is not obtained.  J Clin Neurol 2010;6:224-226
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Introduction
Myasthenia gravis (MG) can be aggravated by various auto-
immune or rheumatologic diseases, thyroid dysfunction, and 
infectious conditions. These conditions may not only interfere 
with immunosuppressive treatment, but they may also exacer-
bate myasthenic weakness by immune dysregulation.
1
Tuberculous infection is common in developed countries due 
to an increase in immigration, the pandemic outbreak of HIV 
infection, and drug-resistant mycobacterium tuberculosis (My-
cobacterium tuberculosis) infection.
2 Most tuberculous infec-
tions are located in the lung, but reported 5-15% of such infec-
tions affect extrapulmonary tissues. In addition, lymph nodes 
are reportedly involved in 30-50% of patients with extrapul-
monary tuberculosis, the most frequently involved site being 
the cervical lymph nodes.
3,4 However, isolated mediastinal tu-
berculous lymphadenitis (MTL) without any pulmonary man-
ifestations is extremely uncommon.
MG is known to be exacerbated during unsuspected infec-
tious illnesses such as tuberculous infection. It has been dem-
onstrated that corticosteroid therapy in patients with unrecog-
nized or untreated tuberculosis can lead to the reactivation of 
M. tuberculosis.
5 However, it is not easy to predict the possi-
bility of isolated MTL due to the lack of constitutional tuber-
culous symptoms and signs. We present herein a case of myas-
thenic weakness aggravated by steroid-induced isolated MTL.
Case Report
A 56-year-old woman with previously well-controlled MG was 
admitted to our hospital because of myasthenic symptoms that 
had progressively aggravated over a period of several months. 
She did not complain of fever, weight loss, cough, sputum, or 
sweating at nighttime, although she did complain of mild gas-
tric discomfort. Her history was unremarkable except for the 
MG, and a family history of tuberculous infection was absent. 
She had been diagnosed with ocular MG in a private neurolo-
gy clinic 2 years previously. Her initial symptom was only fl-
uctuating ptosis of the right eyelid, which responded to pyri-
dostigmine (180 mg/day). At the onset of MG symptoms, the 
diagnosis of MG was made on the basis of increased levels of 
anti-acetylcholine receptor antibody (AChR-Ab, 2.3 nmol/L; 
normal, 0.2 nmol/L) and an abnormal decremental response 
(-11%, -14%, and -14% at stimulation intensities of 2, 3, and  Nam TS et al.
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5 Hz, respectively) in the orbicularis oculi muscle. Computed 
tomography (CT) of the chest revealed normal findings. Small 
dosages of corticosteroids (15 mg/day prednisone) and oral 
pyridostigmine (180-240 mg/day) had been administered to 
control the ocular myasthenia 7 months prior to admission to 
our hospital. However, this patient had been given higher dos-
ages of oral prednisone (30 mg/day) and pyridostigmine (360 
mg/day) because of uncontrolled myasthenic weakness for the 
3 months prior to her admission. On admission to our hospital, 
a neurological examination revealed bilateral ptosis, ophthal-
moplegia, diplopia, mild dysphagia, and generalized muscle 
weakness in all four extremities, without any respiratory symp-
toms. These symptoms were consistent with grade IIB accord-
ing to a modified Osserman’s classification. The serological 
AChR-Ab level was 5.4 nmol/L. We performed laboratory ev-
aluations to determine the presence of various risk factors that 
can exacerbate myasthenic symptoms. The erythrocyte sedi-
mentation rate was 69 mm/h, and the level of C-reactive pro-
tein was within the normal limits. Tests for serum creatine ki-
nase, HIV, hepatitis B surface antigen, antinuclear antibody, an-
tineutrophil cytoplasmic antibody, anti-SS-A/B, anti-smooth-
muscle antibody, rheumatoid factor, proteins C and S, CH50/
C3/C4 complement, and lupus-anticoagulant were negative. Th-
yroid function tests were also negative. A chest X-ray did not 
show any parenchymal, pleural, or mediastinal involvement. A 
follow-up chest CT revealed multiple enlarged lymph nodes 
in the anterior mediastinum without any thymic abnormalities 
or pulmonary tuberculosis (Fig. 1). Transbronchial needle as-
piration was not performed due to the deep location of the af-
fected lymph node. Lymph node biopsy by mediastinoscopy 
revealed chronic granulomatous inflammation without any ma-
lignant cells. We considered that the newly developed isolat-
ed MTL was an aggravating factor for MG. An empirical an-
tituberculous regimen of isoniazid, rifampicin, ethambutol, and 
pyrazinamide was started. In addition, oral pyridostigmine (360 
mg/day) combined with azathioprine (100 mg/day) and no oral 
prednisone were administered in order to control aggravated 
myasthenic weakness. Two months after mediastinal lymph 
node biopsy, M. tuberculosis was isolated from the biopsied spe-
cimen culture. At a 12-month follow-up examination, ocular 
and bulbar symptoms, and generalized muscle weakness per-
sisted. Follow-up chest CT revealed an increase in the size of 
the previously observed mediastinal lymph nodes. We regard-
ed this to be a treatment failure due to multidrug-resistant tu-
berculosis, and second-line antituberculosis agents including 
prothionamide, cycloserine, and para-aminosalicylic acid were 
administered for the following 24 months. Three years after the 
administration of second-line antituberculosis agents, the pa-
tient achieved complete clinical remission of MG symptoms, 
and she has been off the anticholinesterase inhibitor and aza-
thioprine medication for more than 12 months.
Discussion
MG is a neuromuscular transmission disorder that is character-
ized by easy fatigability and muscle weakness. It is an autoim-
mune disease that is associated with antibodies such as AChR-
Ab at the neuromuscular junction. Patients with MG have an 
increased incidence of several associated conditions that may 
exacerbate the myasthenic weakness, including hyper- or hy-
pothyroidism, occult infection, medical treatment for other dis-
orders, emotional stress, and pregnancy.
1 In our case the only 
MG-aggravating factor present was isolated MTL. Approxi-
mately 85% of all tuberculous infections occur in the lungs, the 
remaining being found in the extrapulmonary tissues. Typical-
ly 30-50% of extrapulmonary tuberculous infections affect the 
lymph nodes.
3,4 Geldmacher et al.
3 reported that lymph node 
involvement in extrapulmonary tuberculosis is most frequent-
ly found in the cervical lymph nodes, followed by the medias-
tinal, axillary, and inguinal lymph nodes, and that the incidence 
of lymph node tuberculosis without pulmonary involvement 
is approximately 5.2%, whereas that of isolated MTL is around 
Fig. 1. The contrast-enhanced computed tomography images of the chest in the patient with mediastinal tuberculous lymphadenitis. A: Mul-
tiple lymphadenopathies with conglomerate and homogenous enhancement in the anterior mediastinum, right lower paratracheal area, and 
aortopulmonary window. B and C: Enlarged lymph nodes with central low attenuation and peripheral rim enhancement in both hilar areas 
(arrow).
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1.4%. Therefore, isolated MTL is not generally suspected be-
cause of the lack of constitutional symptoms, absence of an 
exposure history and palpable lymph nodes, and its low inci-
dence.
2,3 Thus, the diagnosis and treatment of tuberculous in-
fections in patients with isolated MTL may often be signifi-
cantly delayed. Unfortunately, it has been reported that corti-
costeroid therapy in patients with untreated or unrecognized tu-
berculosis results in overwhelming disease and consequent 
death.
Corticosteroids are the most commonly used and most con-
sistently effective immunosuppressive agents in the treatment 
of MG. They may reduce the serum AChR-Ab level and dimi-
nish the AChR reactivity of peripheral blood lymphocytes.
6 
However, prolonged administration of corticosteroids often in-
duces an increased susceptibility to infection. Patients who 
are given prolonged corticosteroid therapy may be at risk for 
the exacerbation of primary tuberculosis and the reactivation 
of inactive tuberculosis, although the precise risk has not been 
elucidated.
7 In our case the patient complained of further ag-
gravated myasthenic weakness after corticosteroid adminis-
tration. It is generally known that administration of corticoste-
roids can lead to a transient exacerbation of myasthenic weak-
ness within several weeks. However, the condition of our pa-
tient was inconsistent with steroid-induced exacerbation of 
MG because she complained of gradual myasthenic weakness 
over a period of several months, and the initial daily dose of 
oral prednisone was low.
Together these findings suggest that the possibility of tuber-
culous infections is often ignored in patients with various types 
of tuberculous infections without pulmonary symptoms or pal-
pable lymph nodes. Therefore, in MG patients receiving long-
term corticosteroid therapy, careful practical approaches to 
the screening of tuberculosis by chest radiography, tubercu-
lin skin testing, and sputum examination are mandatory. In ad-
dition, further diagnostic tools such as CT or magnetic reso-
nance imaging are required because extrapulmonary tubercu-
losis occasionally occurs in anatomic regions such as the lym-
ph nodes and the skeletal or genitourinary systems. If chest CT 
to detect tuberculous infections had been performed sooner 
after the symptom aggravation in our patient, the comorbidity 
and treatment duration may have been reduced.
In conclusion, the possibility of chronic infections such as 
tuberculosis should be considered in MG patients receiving long-
term corticosteroids who show progressive exacerbation of my-
asthenic weakness without other aggravating factors.
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